A Proper Sequence for the Treatment of B16 Melanoma: Chemotherapy, Surgery, and Immunotherapy

Pendergrast, W. Jefferson; Drake, Walter P.; Mardiney, Michael R.

doi:10.1093/jnci/57.3.539

Cited by 18 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nonspecific immunostimulants such as BCG, C. parvum have been efficacious even for clinical tumors such as lung cancer, melanoma, etc. [7,8], However, it is still controversial whether nonspecific immunotherapy in addition to cytoreductive chemotherapy is effective or not for advanced solid tumor [9], and this important question should be studied more in detail by using an appropriate solid animal tumor model. In the field of leukemia immunochemotherapy, Murphy and LoBuglio [10] reported that guinea pig leukemia may represent a useful model for exploring the effect of immunomodulation.…”

Section: Discussionmentioning

confidence: 99%

Effect of 1(4-Amino-2-methyl-5-pyrimidinyI), methyl-3-(2-chloroethyl)-3-nitrosourea Hydrochloride (ACNU) on Sato Lung Carcinoma (SLC)

Saijo¹,

Niitani²,

Irimajiri³

et al. 1979

Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of 1(4-Amino-2-methyl-5-pyrimidinyI), methyl-3-(2-chloroethyl)-3-nitrosourea Hydrochloride (ACNU) on Sato Lung Carcinoma (SLC)

Saijo¹,

Niitani²,

Irimajiri³

et al. 1979

Oncology

View full text Add to dashboard Cite

show abstract

“…There are experimental animal data and theoretic considerations to support the use of preoperative (neoadjuvant) chemotherapy [29]. Experimental tumors are most effectively eradicated when chemotherapy is given before surgery.…”

Section: Historical Perspectivementioning

confidence: 99%

Multimodality treatment of cancer arising from Barrett's epithelium

Roth

1995

World j. surg.

View full text Add to dashboard Cite

Adenocarcinoma arising in Barrett's epithelium is seen with increasing frequency. Most patients are diagnosed with advanced cancer, and the overall survival is less than 15%. Therefore novel preventive and therapeutic strategies are needed. Molecular markers are being developed that may predict which patients with Barrett's will develop cancer. Combined modality therapy with chemotherapy and surgery has been studied extensively in clinical trials. Although the results of these studies suggest improved survival, definitive proof must await completion of ongoing randomized trials. Surgical resection of adenocarcinoma provides restoration of swallowing and local tumor control with a low operative mortality.

show abstract

“…From rapidly accumulating knowledge we hope to be able to construct a rational therapy of the future which will include surgery, chemotherapy, and immunotherapy (Pendergrast et al 1976, Al-Sarraf & Costanzi 1978, Kaufman et al 1978, Oettgen 1977, Old 1977 in a successful multimodality attack on metastatie malignant melanoma.…”

Section: Adoptive Immunotherapymentioning

confidence: 99%

Immunotherapy of Melanoma

Nathanson¹

1979

J Cutan Pathol

View full text Add to dashboard Cite

Malignant melanoma is a disease characterized by clinical evidence of host defense, possibly immunologically mediated. It is a disease which tends to be refractory to both radiotherapy and chemotherapy. Immunotherapy has been used in three phases of the disease. 1. Intralesional immunotherapy with a nonspecific immune adjuvant in patients with local intradermal or soft tissue recurrence. This treatment produces approximately 15% regression of both injected and uninjected lesions, and about 60% regression of injected lesions only. Both clinical and laboratory evidence suggests that this regression is immunologically mediated. 2. Patients with surgical removal of all clinically demonstrable tumor, either primary disease alone or regional node recurrence, active nonspecific, and specific, immunotherapy has been used in an adjuvant setting. There is considerable controversy about the benefits accruing to such immunotherapy, but most large scale prospective and randomized studies have suggested that if benefit does result it is modest in degree and probably cannot be measured in terms of increase in cure rate. 3. Immunotherapy has also been used as a nonspecific active adjuvant to single drug or polychemotherapy in patients with disseminated melanoma. Whereas complete response rate may be slightly increased by this maneuver there is no convincing evidence that immunotherapy markedly increases the total objective response rate to polychemotherapy, and survival is only marginally superior when immunotherapy is added to chemotherapy in this setting. Further studies need to be done with active specific immunotherapy with tumor cell membrane extracts; as an adjuvant in patients with minimal body burden of tumor cells; and to study the inaction between chemotherapy and immunotherapy in this disease. Furthermore, studies of chemically defined fractions of either bacterial cell wall or tumor cell extracts must be evaluated both in terms of their ability to augment cell mediated immune responses in the melanoma patient, and also in terms of their ability to induce objective benefit for the patient. The possible use of immunotherapy in patients with primary melanoma has been briefly explored but needs further study. Possible additive effects with radiotherapy and immunotherapy should also be looked at in this disease utilizing high dose fractions and other new forms of radiotherapeutic technique.

show abstract

A Proper Sequence for the Treatment of B16 Melanoma: Chemotherapy, Surgery, and Immunotherapy

Cited by 18 publications

References 0 publications

Effect of 1(4-Amino-2-methyl-5-pyrimidinyI), methyl-3-(2-chloroethyl)-3-nitrosourea Hydrochloride (ACNU) on Sato Lung Carcinoma (SLC)

Effect of 1(4-Amino-2-methyl-5-pyrimidinyI), methyl-3-(2-chloroethyl)-3-nitrosourea Hydrochloride (ACNU) on Sato Lung Carcinoma (SLC)

Multimodality treatment of cancer arising from Barrett's epithelium

Immunotherapy of Melanoma

Contact Info

Product

Resources

About